All In Biotech

Drug Trial Radar · NCT00098293

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

A Multicenter, Randomized, Double-Blind, Comparative Trial Of A Novel CCR5 Antagonist, UK-427,857, In Combination With Zidovudine/Lamivudine Versus Efavirenz In Combination With Zidovudine/Lamivudine For The Treatment Of Antiretroviral-Naive HIV-1 Infected Subjects

Last checked: Nov 20, 2026Latest source record: Oct 9, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 916 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

916

Actual

Start

Nov 2004

Primary completion

Apr 2007

Study completion Dec 2012

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
Collaborators
Pfizer
First posted
Dec 7, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes). In HIV-1 infected patients, maraviroc (UK-427,857) given as monotherapy for 10 days reduced HIV-1 viral load by up to 1.6 log, consistent with currently available agents. Safety and toleration have been studied in over 400 subjects for up to 28 days at 300 mg twice daily. No significant effects were seen on the QTc interval. The goal of this study is to compare the safety and efficacy of maraviroc (UK-427,857) versus efavirenz, when each are combined with two other antiretroviral agents, in patients who are previously naive to antiretroviral therapy. This study will involve approximately 200 centers from around the world to achieve a total randomized subject population of 1071 subjects. Patients will be randomly assigned to one of three groups: maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily), Maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily) or efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily). The study will enroll over approximately an 18 month period (5 months Phase 2b run-in, 13 months Phase 3) with 96 weeks of treatment. This may be extended for an additional 3 years depending on the results at 96 weeks. Physical examinations will be performed at study entry, weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84 and 96. Blood samples will also be taken at study entry, weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84 and 96. Additionally, blood samples will be drawn twice, at least 30 minutes apart, at weeks 2 and 48 for maraviroc (UK-427,857) pharmacokinetic analysis. As part of this clinical study a blood sample will be taken for non-anonymized pharmacogenetic analysis. Patients will undergo a 12-lead electrocardiogram at study entry, weeks 24, 48 and 96. A computerized tomography (CT) scan will also be performed, at selected centers, at study entry and week 96. Patients will be asked to complete a symptom distress questionnaire at study entry, weeks 12, 24, 48 and 96.

Conditions

  • HIV-1

Interventions

  • Maraviroc + Zidovudine/LamivudineDrug

    maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)

  • Efavirenz + Zidovudine/LamivudineDrug

    efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)

  • Maraviroc (UK-427,857) + Zidovudine/LamivudineDrug

    maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) PopulationTime frame: Week 48
  2. Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) PopulationTime frame: Week 48

Locations

144 sites in 14 countries. Site status is shown where the registry gives one.

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Birmingham, Alabama

  • Pfizer Investigational Site

    Beverly Hills, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Los Angeles, California

  • Pfizer Investigational Site

    Newport Beach, California

  • Pfizer Investigational Site

    Oakland, California

  • Pfizer Investigational Site

    Sacramento, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    San Francisco, California

  • Pfizer Investigational Site

    Aurora, Colorado

  • Pfizer Investigational Site

    Jacksonville, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami, Florida

  • Pfizer Investigational Site

    Miami Beach, Florida

  • Pfizer Investigational Site

    Orlando, Florida

  • Pfizer Investigational Site

    Sarasota, Florida

  • Pfizer Investigational Site

    Tampa, Florida

  • Pfizer Investigational Site

    Atlanta, Georgia

  • Pfizer Investigational Site

    Chicago, Illinois

  • Pfizer Investigational Site

    Indianapolis, Indiana

  • Pfizer Investigational Site

    Baltimore, Maryland

  • Pfizer Investigational Site

    Boston, Massachusetts

  • Pfizer Investigational Site

    Boston, Massachusetts

  • Pfizer Investigational Site

    Boston, Massachusetts

  • Pfizer Investigational Site

    Springfield, Massachusetts

  • Pfizer Investigational Site

    Omaha, Nebraska

  • Pfizer Investigational Site

    Albany, New York

  • Pfizer Investigational Site

    Brooklyn, New York

  • Pfizer Investigational Site

    Flushing, New York

  • Pfizer Investigational Site

    Manhasset, New York

  • Pfizer Investigational Site

    New York, New York

  • Pfizer Investigational Site

    Huntersville, North Carolina

  • Pfizer Investigational Site

    Cincinnati, Ohio

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma

  • Pfizer Investigational Site

    Oklahoma City, Oklahoma

  • Pfizer Investigational Site

    Philadelphia, Pennsylvania

  • Pfizer Investigational Site

    Columbia, South Carolina

  • Pfizer Investigational Site

    Dallas, Texas

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.